Episodes

  • EP 161: How large language models can help build immunotherapies with Michelle Teng of Etcembly Ltd.

    EP 161: How large language models can help build immunotherapies with Michelle Teng of Etcembly Ltd.
    Nov 14 2024
    In this week’s episode, Patrick is joined by Michelle Teng, ​​CEO and Co-Founder of Etcembly Ltd and Founding Executive Director and Chief Scientific Officer of SynaptixBio. Michelle explains how her team is training large language models (LLMs) to analyze immune system data and how the company’s Long Term Survivor Study is helping identify T-cell profiles associated with sustained cancer remission. She also speaks to her own experience of ultra-rare genetic disease.
    Show more Show less
    51 mins
  • EP 160: Artificial Intelligence, GWAS in Drug Discovery, and Career Insights with Dr. Eric Fauman, Executive Director and Head of Computational Biology in the Internal Medicine Research Unit at Pfizer

    EP 160: Artificial Intelligence, GWAS in Drug Discovery, and Career Insights with Dr. Eric Fauman, Executive Director and Head of Computational Biology in the Internal Medicine Research Unit at Pfizer
    Nov 7 2024
    In this episode, we welcome Dr. Eric Fauman, Executive Director and Head of Computational Biology in the Internal Medicine Research Unit at Pfizer. Eric and Patrick discuss facilitating efficient identification of potential drug targets and the role of artificial intelligence in genetics research and drug discovery. Please note that Eric has kindly shared some interesting research that was mentioned in the podcast. It is pasted at the end of the show notes.
    Show more Show less
    52 mins
  • EP 159: Engineering macrophages to tackle rare disease with Noam Baumatz of Noga Therapeutics

    EP 159: Engineering macrophages to tackle rare disease with Noam Baumatz of Noga Therapeutics
    Oct 31 2024
    In this episode, we’re joined by Noam Baumatz, CEO and Co-Founder of Noga Therapeutics, a company dedicated to developing gene therapies for rare and severe diseases through engineering macrophages. Motivated by his highly personal experience of rare disease, Noam founded Noga to develop the type of gene therapies his daughter was unable to access. He and Patrick discuss his work with parents and families affected by rare disease, the road to effective, financially accessible gene therapies, and Noam’s previous work in traditional Chinese medicine.
    Show more Show less
    44 mins
  • EP 158: Research Roundup with Dr Veera: Discoveries in neurogenetics, evolution, cardiac arrhythmias, and more!

    EP 158: Research Roundup with Dr Veera: Discoveries in neurogenetics, evolution, cardiac arrhythmias, and more!
    Oct 23 2024
    Join us as we welcome back Dr. Veera Rajagopal, a discovery scientist at Regeneron with an interest in human genetics and drug target discovery in neuroscience and psychiatry. If you’re a regular listener of The Genetics Podcast, you may be familiar with Dr. Veera’s annual round-up episodes, and more recently, his quarterly appearances on the show. We’re pleased to bring you the latest quarterly roundup, during which Dr. Veera and Patrick walk through the most recent developments in genetics, drug discovery, and precision medicine. In this episode, Dr. Veera and Patrick dive into a wide variety of topics, including: - The evolution of skin color in humans - The potential of a novel tau isoform for Alzheimer’s treatment - Protective mechanisms of tomoregulin-1 against herpes simplex virus - The discovery of a new noncoding Mendelian disease mechanism linked to cardiac arrhythmias - A comparative analysis of whole genome versus whole exome sequencing for gene discovery. Tune in now, and don’t forget to check out Veera’s substack, GWAS Stories, and his Twitter, @doctorveera. Additionally, we’re excited to invite you to an in-person meetup for The Genetics Podcast during the ASHG Annual Meeting in Denver, CO! Over the years, we’ve had the honor of speaking with leading voices across science, industry, patient advocacy, and policy. Now, we’re bringing this incredible community together face-to-face. Join us on the evening of Thursday, November 7. To RSVP, visit: https://lu.ma/geneticspodASHG.
    Show more Show less
    1 hr and 12 mins
  • EP 157: Bridging genomics, business, and equity in healthcare access with Mark Taylor of LGC Group

    EP 157: Bridging genomics, business, and equity in healthcare access with Mark Taylor of LGC Group
    Oct 17 2024
    In this episode, Patrick speaks with Mark Taylor, Head of Strategic Partnerships at LGC Group, about bridging the gap between genomics innovation and equitable healthcare. They discuss Mark's work with the National Institute for Health Research (NIHR), challenges in scaling precision therapies for the NHS, and strategies for engaging underrepresented populations. Additionally, we’re excited to invite you to an in-person meet up for The Genetics Podcast during the ASHG Annual Meeting in Denver, CO! Over the years, we’ve had the honor of speaking with leading voices across science, industry, patient advocacy, and policy. Now, we’re bringing this incredible community together face-to-face. Join us on the evening of Thursday, November 7. To RSVP, visit: https://lu.ma/geneticspodASHG.
    Show more Show less
    36 mins
  • EP 156: The Genetics Podcast In-Person Event!

    EP 156: The Genetics Podcast In-Person Event!
    Oct 11 2024
    Join us at our first in-person podcast event! We will be hosting a reception during the ASHG Annual Meeting in Denver, CO. The event will be held on the evening of Thursday 7 November. ​Please submit your information in this form (https://lu.ma/geneticspodASHG) to signify your interest in attending!
    Show more Show less
    2 mins
  • EP 155: Adeno-associated virus as a delivery vector for genetic eye disease treatment, with Paul Wille of Abeona Therapeutics

    EP 155: Adeno-associated virus as a delivery vector for genetic eye disease treatment, with Paul Wille of Abeona Therapeutics
    Oct 10 2024
    This week Patrick is joined by Paul Wille, Director of Product Development at Abeona Therapeutics. They discuss the use of adeno-associated virus (AAV) as a vector for gene therapy delivery, outline its limitations and benefits, and hone in its potential in the context of genetic eye disorders. Paul also shares his journey from academia to industry and emphasizes the importance of building on existing technologies to advance the field. Additionally, please consider joining us at our first in-person podcast event! We will be hosting a reception during the ASHG Annual Meeting in Denver, CO. The event will be held on the evening of Thursday 7 November. ​Please submit your information in this form (https://lu.ma/geneticspodASHG) to signify your interest in attending!
    Show more Show less
    32 mins
  • EP 154: Pioneering early disease detection through wearable devices and regular monitoring with Dr. Mike Snyder

    EP 154: Pioneering early disease detection through wearable devices and regular monitoring with Dr. Mike Snyder
    Oct 3 2024
    In this episode, Dr. Mike Snyder, Director of the Center for Genomics and Personalized Medicine at Stanford School of Medicine, shares his pioneering work on health monitoring using multiomics and wearables. The conversation spans personalized aging, the challenges of implementing precision medicine in mainstream healthcare, and Dr. Snyder's vision for a future where proactive health monitoring predicts illness before symptoms appear, keeping people healthier longer. Tune in for a fascinating episode centered on preventative medicine!
    Show more Show less
    41 mins